US-guided optical technique reduces biopsy rate
An ultrasound-guided diffuse optical technique may lower the rate at which women undergo breast biopsies for suspicious lesions, according to a study published in Radiology.
An ultrasound-guided diffuse optical technique may lower the rate at which women undergo breast biopsies for suspicious lesions, according to a study published in Radiology.
Diffuse optical tomography is a noninvasive imaging technique that measures light absorption within tissue to quantify blood content and blood oxygen levels. Once ultrasound locates the lesion, DOT is performed by shining infrared light into the area and measuring light absorption at two optical wavelengths.
In the study, 178 consecutive women underwent the technique on a previously identified solid lesion followed by a biopsy. Researchers computed total hemoglobin levels from the light absorption measured at two wavelengths and correlated the measurements with biopsy results. Tissue sample examinations revealed two in situ carcinomas, 35 carcinomas that measured <2 cm, 24 carcinomas >2 cm, and 114 benign lesions (2010;256:367-378). The sensitivity (92%) and specificity (93%) of the technique were greatest when evaluating cancers <2 cm in size.
DOT holds promise as an adjunct to diagnostic mammography and ultrasound for distinguishing early stage invasive breast cancers from benign lesions, the researchers said.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
GE HealthCare to Launch PET MPI Agent Flyrcado at ACC Conference
March 28th 2025The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
